Core Insights - Guangzhou Huaten Biomedical Technology Co., Ltd. has recently completed a B+ round of financing, raising several tens of millions of RMB [1] - The company, founded in 2019 and based in Guangzhou, focuses on research and experimental development [1] - The company has a registered capital of 15.019 million RMB and has completed its B+ round financing by 2026 [1] Company Overview - The legal representative of Guangzhou Huaten Biomedical Technology Co., Ltd. is Xie Shuilin [1] - The company has made investments in four other enterprises and holds 17 trademark registrations and 19 patents [1] - The company possesses 40 administrative licenses [1] Shareholders - The shareholders of Guangzhou Huaten Biomedical Technology Co., Ltd. include Xie Shuilin, Guangzhou Huaten Investment Consulting Partnership (Limited Partnership), Guangzhou Zhenhua Venture Capital Fund Partnership (Limited Partnership), Zhuhai Hengqin Zhineili Investment Partnership (Limited Partnership), and Guangzhou Yanghe Jiansheng Venture Capital Fund Partnership (Limited Partnership) [1]
广州华腾生物医药科技有限公司获“B+轮”融资，金额数千万人民币
Sou Hu Cai Jing·2026-01-05 07:24